Mankind Pharma Completes Acquisition Of Remaining Stake In Upakarma Ayurveda

On Wednesday, Indian equity benchmarks traded lower, with the benchmark Nifty 50 index declining 1.31 per cent to 23,175.10. Despite the broader market weakness, Mankind Pharma share price traded at Rs 2,319.45, up 0.83 per cent from the previous close. The stock remained in focus after the company announced the acquisition of the remaining 10 per cent stake in Upakarma Ayurveda Private Limited, making the company an indirect wholly owned subsidiary.

Mankind Pharma Acquires Remaining Stake In Upakarma Ayurveda

Mankind Pharma Limited informed the exchanges that its wholly owned subsidiary, Mankind Lifesciences Private Limited (MLS), has completed the acquisition of the remaining 10 per cent equity stake in Upakarma Ayurveda Private Limited.

The acquisition was executed through a Share Purchase Agreement dated June 2, 2026, for a cash consideration of Rs 75 lakh. The payment will be made in two tranches. Following the completion of the transaction, MLS now holds 100 per cent of Upakarma Ayurveda, making it a wholly owned subsidiary of MLS and a step-down wholly owned subsidiary of Mankind Pharma.

Transaction Details And Business Profile

The company stated that the acquisition was carried out as a related party transaction on an arm's length basis. It further clarified that the promoters and promoter group of Mankind Pharma do not have any interest in the transaction.

Upakarma Ayurveda was incorporated on November 28, 2017, and is engaged in the trading and sale of ayurvedic, herbal and nutraceutical products in India. The company became a step-down subsidiary of Mankind Pharma in November 2022 after MLS acquired a 90 per cent stake.

Upakarma has an authorised share capital of Rs 2 crore and a paid-up share capital of Rs 1.80 crore.

Upakarma Financial Details

For the financial year ended March 31, 2026, Upakarma Ayurveda reported a turnover of Rs 18.02 crore. The company had recorded turnover of Rs 13.06 crore in FY25 and Rs 23.04 crore in FY24.

Mankind Pharma stated that the acquisition is expected to support better operational efficiencies through streamlined business processes. The company also noted that no governmental or regulatory approvals were required for completing the transaction, which was concluded on June 2, 2026.

Shareholding And Stock Performance

As of June 3, 2026, around 12:00 PM, Mankind Pharma shares were trading at Rs 2,321.20, up 0.99 per cent from the previous closing price of Rs 2,298.50.

The stock has delivered returns of negative 4.70 per cent over the past one year, 7.19 per cent over two years and 56.91 per cent over three years. During the last 52 weeks, the stock touched a high of Rs 2,699.80 and a low of Rs 1,922.45.

According to the latest shareholding pattern, foreign institutional investors reduced their stake to 10.24 per cent from 11.34 per cent in the previous quarter, while domestic institutional investors increased their holding to 14.42 per cent from 13.22 per cent.

About Mankind Pharma

Mankind Pharma Ltd develops, manufactures and markets a wide range of pharmaceutical formulations across acute and chronic therapeutic segments. The company also has a presence in the consumer healthcare segment through products including condoms, pregnancy detection kits, antacid powders, vitamin and mineral supplements, oral contraceptives and medicated anti-acne preparations.

Founded in 1991, the company operates 32 manufacturing facilities and six research and development centres. Mankind Pharma has a pan-India distribution network and a global presence through 38 subsidiaries operating across multiple geographies.

What are your thoughts on Mankind Pharma's acquisition of the remaining stake in Upakarma Ayurveda? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.